Company type | Sociedad Anónima |
---|---|
BMAD: ALM | |
ISIN | ES0157097017 |
Founded | 1944 |
Founder | Antonio Gallardo Carreras |
Headquarters | |
Area served | International |
Products | Ebglyss, Ilumetri, Wynzora, Klisyri, Seysara, Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Actikerall. [1] |
Revenue | €898.8 million (2023) [2] |
€33.5 million (2022) [3] | |
Total assets | €2.302 billion (2022) [3] |
Number of employees | 1,904 (2023) [4] |
Website | www |
Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944. [5]
In 2023, the company generated total revenues of €898.8 [6] million and was the leading European company in medical dermatology.
With approximately 1,904 employees (2023), it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA. [7]
Almirall SA was founded in 1944 in Spain. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company’s internal R&D team. In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched aceclofenac and a year later opened its second foreign subsidiary, in Portugal. The company's new headquarters were opened in Barcelona, in 1994. In 1997 Almirall and Prodesfarma merged their interests. [8]
In 2000 the FDA approved anti-migraine agent almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008), Nordic Countries (2010) [9] and Netherlands (2013).
In 2005 the business acquired the commercial rights for Sativex in Europe for the treatment of spasticity associated to multiple sclerosis. In 2006, the company opened its new R&D Centre based in Sant Feliu de Llobregat as well as the acquisition of the Centre of Excellence for Inhalation Technology.
In 2007, the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from Shire plc.
In 2011, Almirall launched Actikerall prescribed for the local treatment of actinic keratosis.
In 2012, Almirall opened its first North America subsidiary, based in Canada [9] and launched aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the United States under the brand Tudorza Pressair. The business also launched Monovo, for the treatment of inflammatory skin diseases such as psoriasis.
Almirall began a concentrated focus on medical dermatology in 2013, [10] following the acquisition of another specialist dermatology company, Aqua Pharmaceuticals. The company launched linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C) and opened its Netherlands subsidiary. [9]
In 2014 Almirall divested its rights to its respiratory franchise to Astrazeneca focussing on the dermatology, later in 2015 declaring its strategic intention to become a leading pharmaceutical company in the field of dermatology and continuing with its expansion by acquiring Poli Group Holding and ThermiGen LLC in 2016. [11]
In May 2022, a new generational change took place within the founding family, with the replacement of Jorge Gallardo Ballart by his son Carlos Gallardo Piqué at the head of the non-executive presidency of the company. [12] Six months later, Carlos Gallardo also assumed the executive management.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona [13] in Spain. Highlighted among the international alliances are those with the Imperial College London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. [14] In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.
The company also has three production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 13 affiliates in Germany, Austria, Belgium-Luxembourg, the United States, France, the Netherlands, Italy, the Nordic countries, Poland, Portugal, the United Kingdom-Ireland, Spain, and Switzerland. [15]
2010 | 2011 | 2012 | 2013 | 2014 [16] | 2015 [17] | 2016 [18] | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total revenue | €1002,1 MM | €873,1 MM | €900,2 MM | €825,5 MM | €1.407,4 MM | €769 MM | €859,3 MM | €755,8 MM | €811,0 MM | €908,4 MM | €814,5 MM | €836,5 MM | €878,5 MM | €898.8 MM |
Net sales | €882.4 MM | €768.4 MM | €682.9 MM | €692.9 MM | €786.4 MM | €685 MM | €764,4 MM | €639,4 MM | €756,9 MM | €853,1 MM | €807,4 MM | €827,2 MM | €863,2 MM | €894.5 MM |
% International sales | - | 50% | 60% | 62% | 70% | 68% | 70% | 69% | ||||||
% Sales of own medicines | - | - | 59% | 64% | 70% | 67% | 77% | 68% | ||||||
Investment in R&D [19] | 16.4% of net sales | 18.8% of net sales | 23.4% of net sales | 18% of net sales | 12.8% of net sales | 9.7% of net sales | 12,9% of net sales | 13,7% of net sales | 11,6% of net sales | 10,8% of net sales | 10% of net sales | 9% de of net sales | 12% of net sales | 12% of net sales |
Employees | 2,831 | 2,765 | 2,871 | 3,000 | 2,100 | 1,889 | 1,975 | 1.832 | 1.805 | 1.765 | 1.785 | 1.786 | 1.845 | 1.904 |
Affiliates | 13 | 13 | 14 | 15 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 15 |
R&D Centres [20] | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 1 | 1 |
Production centres | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Brand | Active ingredient | Pathology |
---|---|---|
Ebastel | Ebastine | Allergy |
Monodox | Doxycycline | Severe Acne |
Acticlate | Doxycycline hyclate | Severe Acne |
Almogran | Almotriptan | Migraine |
Tesavel and Efficib | Sitagliptin and sitagliptin/metformin | Diabetes |
Solaraze | Diclofenac sodium | Actinic keratosis |
Airtal | Aceclofenac | Musculoskeletal pain |
Decoderm | Fluprednidene | Fungal dermatitis |
Cordran | Fludroxycortide | Inflammation and itching of the skin |
Parapres | Candesartan | Hypertension |
Almax | Almagate | Acidity |
Balneum | Urea | Dry skin |
Cleboril | Clebopride | Gastroesophageal reflux disease |
Actikerall | 5-Fluorouracil / salicylic acid | Actinic keratosis |
Sativex | Nabiximols | Spasticity in Multiple Sclerosis |
Monovo | Mometasone | Psoriasis |
Ilumetri | Tildrakizumab | Psoriasis |
Ebglyss | Lebrikizumab | Atopic Dermatitis |
Wynzora | Calcipotriol/Betamethasone | Psoriasis |
Klisyri | Tirbanibulin | Actinic keratosis |
Seysara | Sarecycline | Acne |
Physiorelax | Helenalin | Muscle and ligament massage |
Dassault Systèmes SE is a French multinational software corporation which develops software for 3D product design, simulation, manufacturing and other 3D related products.
Nestlé S.A. is a Swiss multinational food and drink processing conglomerate corporation headquartered in Vevey, Switzerland. It has been the largest publicly held food company in the world, measured by revenue and other metrics, since 2014. It ranked No. 64 on the Fortune Global 500 in 2017. In 2023, the company was ranked 50th in the Forbes Global 2000.
Alliance Healthcare, formerly Alliance UniChem, is a wholesaler, distributer and retailer of pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres, and hospitals from over 288 distribution centres in 11 countries.
Glénat Éditions SA is a French publisher with its head office in Grenoble. Their products include comic albums and manga in France, Benelux, and in the past Spain; it was founded by Jacques Glénat. The Benelux subsidiary, Glénat Benelux N.V., is located in Brussels, Belgium. The Switzerland subsidiary, Glénat Éditions (Suisse) SA, has its headquarters in Nyon. The Spanish subsidiary had its head office in Barcelona.
Serono was a biotechnology company headquartered in Geneva, Switzerland. It was acquired by the German pharmaceutical company Merck in 2006. The company was founded as the Serono Pharmacological Institute by Cesare Serono in 1906 in Rome, Italy. A key step in its development was the discovery of a method of extracting urinary gonadotropins by Dr. Piero Donini. Serono was incorporated in 1987 and the holding company, Ares-Serono S.A., changed its name to Serono S.A. in May 2000.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Galderma S.A. is a Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé, it has been held by a consortium of private institutional investors since 2019.
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.
LEO Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen The company is 100% integrated into a private foundation owned by the LEO Foundation. LEO Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation. In 1945, it was the first producer of penicillin outside the US and UK.
Historically, the city of Barcelona, in the Spanish autonomous community of Catalonia, had a large tramway network. The city's first tram line opened in 1872, but almost all of these historic lines had closed by 1971, being replaced by buses and by the expanding Barcelona Metro. The one remaining line, the Tramvia Blau, was retained as tourist attraction, using historic rolling stock. However at the beginning of the 21st century, two new tram systems, the Trambaix and Trambesòs, opened in the suburbs of the city.
Antoni Vila Casas was a Spanish pharmaceutical executive and philanthropist.
Fly Level SL, styled as LEVEL, is an airline brand under which airlines owned by the International Airlines Group (IAG) operate low-cost flights. The brand has a registered office in Madrid, Spain.
PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index.
HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services.
{{cite web}}
: CS1 maint: archived copy as title (link){{cite web}}
: CS1 maint: archived copy as title (link){{cite web}}
: CS1 maint: archived copy as title (link)